These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9004110)

  • 41. [Effect of buspirone, a serotonergic 5-HT-1A agonist in cerebellar ataxia: a pilot study. Preliminary communication].
    Trouillas P; Xie J; Getenet JC; Adeleine P; Nighoghossian N; Honnorat J; Riche G; Derex L
    Rev Neurol (Paris); 1995 Dec; 151(12):708-13. PubMed ID: 8787101
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pipamperone and the treatment of impulsive aggressive behaviour].
    Klaassen AA
    Tijdschr Psychiatr; 2008; 50(3):179-83. PubMed ID: 18324605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship of sedative-hypnotic response to self-injurious behavior and stereotypy by mentally retarded clients.
    Barron J; Sandman CA
    Am J Ment Defic; 1983 Sep; 88(2):177-86. PubMed ID: 6638079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The treatment of impulsive and aggressive behavior with nadolol.
    Polakoff SA; Sorgi PJ; Ratey JJ
    J Clin Psychopharmacol; 1986 Apr; 6(2):125-6. PubMed ID: 3700702
    [No Abstract]   [Full Text] [Related]  

  • 45. Paramenstrual aggression in mentally retarded adult ameliorated by buspirone.
    Colella RF; Ratey JJ; Glaser AI
    Int J Psychiatry Med; 1992; 22(4):351-6. PubMed ID: 1293064
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Buspirone for stereotypic movements in elderly with cognitive impairment.
    Helvink B; Holroyd S
    J Neuropsychiatry Clin Neurosci; 2006; 18(2):242-4. PubMed ID: 16720804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serotonergic antidepressant effects on aggressive, self-injurious and destructive/disruptive behaviours in intellectually disabled adults: a retrospective, open-label, naturalistic trial.
    Janowsky DS; Shetty M; Barnhill J; Elamir B; Davis JM
    Int J Neuropsychopharmacol; 2005 Mar; 8(1):37-48. PubMed ID: 15482629
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical comparison of haloperidol with chlorpromazine in mentally retarded children.
    Le Vann LJ
    Am J Ment Defic; 1971 May; 75(6):719-23. PubMed ID: 4932179
    [No Abstract]   [Full Text] [Related]  

  • 49. The use of buspirone with aggressive behavior.
    Hillbrand M; Scott K
    J Autism Dev Disord; 1995 Dec; 25(6):663-4. PubMed ID: 8720034
    [No Abstract]   [Full Text] [Related]  

  • 50. Lithium treatment of behavioural disturbances in patients with defective intellect.
    Müllerová S; Novotná J; Rehan V; Skula E
    Act Nerv Super (Praha); 1974 Aug; 16(3):196. PubMed ID: 4421599
    [No Abstract]   [Full Text] [Related]  

  • 51. An applied dose-response curve of thioridazine with the mentally retarded: aggressive, self-stimulatory, intellectual, and workshop behaviors--a preliminary report.
    Breuning SE
    Psychopharmacol Bull; 1982 Jan; 18(1):57-9. PubMed ID: 6965201
    [No Abstract]   [Full Text] [Related]  

  • 52. [Psychopharmacological therapy of self-injurious behavior in mentally retarded individuals].
    Hässler F; Fegert JM
    Nervenarzt; 1999 Nov; 70(11):1025-8. PubMed ID: 10603598
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Buspirone treatment of psychiatrically hospitalized prepubertal children with symptoms of anxiety and moderately severe aggression.
    Pfeffer CR; Jiang H; Domeshek LJ
    J Child Adolesc Psychopharmacol; 1997; 7(3):145-55. PubMed ID: 9466232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term usefulness of thioridazine for institutionalized mentally retarded patients.
    Heistad GT; Zimmermann RL; Doebler MI
    Am J Ment Defic; 1982 Nov; 87(3):243-51. PubMed ID: 7180884
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Buspirone for the treatment of dementia with behavioral disturbance.
    Santa Cruz MR; Hidalgo PC; Lee MS; Thomas CW; Holroyd S
    Int Psychogeriatr; 2017 May; 29(5):859-862. PubMed ID: 28124634
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stress and self-injurious behavior; hormonal and serotonergic parameters in mentally retarded subjects.
    Verhoeven WM; Tuinier S; van den Berg YW; Coppus AM; Fekkes D; Pepplinkhuizen L; Thijssen JH
    Pharmacopsychiatry; 1999 Jan; 32(1):13-20. PubMed ID: 10071178
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Buspirone in ODD.
    Dunne JE
    J Am Acad Child Adolesc Psychiatry; 1999 Aug; 38(8):942. PubMed ID: 10434482
    [No Abstract]   [Full Text] [Related]  

  • 58. Buspirone in the treatment of posttraumatic stress disorder.
    LaPorta LD; Ware MR
    J Clin Psychopharmacol; 1992 Apr; 12(2):133-4. PubMed ID: 1573035
    [No Abstract]   [Full Text] [Related]  

  • 59. An open trial of buspirone in migraine prophylaxis. Preliminary report.
    Pascual J; Berciano J
    Clin Neuropharmacol; 1991 Jun; 14(3):245-50. PubMed ID: 2070365
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Going "all out" pharmacologically? A re-examination of Berkman and Meyer's "alternative strategies and multiple outcomes in remediation of severe self-injury: going 'all out' nonaversively".
    Linscheid TR; Landau RJ
    Ment Retard; 1993 Feb; 31(1):1-6; discussion 7-14. PubMed ID: 8441347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.